Lincoln Pharmaceuticals Ltd

- The company is currently debt-free and has been for the last 4-5 years. - Capex for the next two years is planned around INR 25-26 crores for the current year and INR 30 crores next year, funded entirely through internal accruals. - The management indicated a preference to avoid taking loans and focus on internal funding for expansion. - However, if new opportunities arise and require additional capital, the company may consider taking loans but as a last resort. - No explicit mention of any imminent or planned fundraising through equity. - Overall, the company aims to remain primarily funded through internal accruals and maintain its debt-free status, with loans considered only if absolutely necessary for growth opportunities.

- Lincoln Pharmaceuticals has planned capex of around INR 25-26 crores for FY25 and around INR 30 crores for FY26, funded through internal accruals. - The company has invested in a Cephalosporin plant, which is already commercialized with WHO and country approvals received; expecting INR 55-65 crores revenue from this unit in FY25. - Additional loan advances have been given gradually for growth initiatives like the Cephalosporin unit and support to vendors for narrow margin products. - The company aims to increase its product lines from 17-18 to 25 to reach INR 1200-1300 crores revenue by leveraging the same markets and fixed costs. - Green energy investments include a 4 MW solar plant and rooftop solar to achieve energy zero status and reduce electricity costs. - Expansion plans may consider debt if needed but priority is on funding growth through internal accruals.

- The company targets a revenue growth of approximately 15% to 18% annually over the next 3-4 years. - Aspirationally, Lincoln Pharmaceuticals aims to reach around INR 1,000 crores within the next 3-4 years. - Domestic market growth is expected through an increase in medical representatives (currently ~600) and expanding coverage. - The export market offers substantial opportunity, focusing on 15-20 core products for scale. - New product launches continue with 20-23 products introduced domestically in FY24, with ongoing approvals internationally. - The Cephalosporin plant is expected to generate INR 55-65 crores this year, contributing to growth. - The company plans to grow segments like derma, cardiac, and diabetic by at least 50% over the next few years. - Overall, the growth strategy is driven by broadening product portfolio, increasing geographic coverage, and enhancing marketing efforts.

- The company targets a revenue growth of approximately 15% to 18% annually over the next 3-4 years, aiming to reach around INR 1,000 crores within that time frame. - For EBITDA margins, management expects to maintain a range of 20% to 22% for FY25 and FY26, with slight fluctuations possible due to industry-wide factors. - There is a focus on expanding product lines from 17-18 currently to 25, which is expected to help achieve revenues of INR 1,200 to INR 1,300 crores. - The Cephalosporin plant commercialization is expected to generate INR 55-65 crores of business in the current fiscal year, contributing positively to profitability. - The company is investing in new molecules, geographic expansion domestically and internationally, and increasing medical representative strength to support growth. - Overall, the growth strategy suggests steady improvement in operating profits and earnings per share (EPS) aligned with the revenue and margin targets.

The transcript does not explicitly mention the current or expected order book or pending orders for Lincoln Pharmaceuticals Limited. However, some related insights include: - The company has a growing export business with product registrations of over 1,500 products across various countries including Africa, Latin America, Southeast Asia, and GCC. - There is ongoing product approval and registration activity which may contribute to future order inflows. - The company is actively expanding its domestic market with 20-23 new product launches in FY24. - Export expansion is supported by a team of around 30-35 people on-ground in various countries promoting products. - The management emphasizes steady growth with a target of INR 1,000 crore revenue in 3-4 years, implying a healthy pipeline to support this. No precise figures for order book or pending orders are disclosed in the call transcript.